Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.68 |
| ▸ | CTSS | P25774 | 1/20 | 0.68 |
| ▸ | CTSK | P43235 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | CCKBR | P32239 | 7/20 | 0.61 |
| ▸ | TACR1 | P25103 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | ACE | P12821 | 1/20 | 0.59 |
| ▸ | REN | P00797 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6426476 | 1.00 | CTSL (0.68) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL27649592 | 1.00 | CTSL (0.68) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL6425621 | 1.00 | CTSL (0.68) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL6424726 | 1.00 | CTSL (0.68) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL6429159 | 1.00 | CTSL (0.68) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL6425618 | 1.00 | CTSL (0.68) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL6426865 | 0.95 | CTSL (0.67) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL6426867 | 0.95 | CTSL (0.67) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL27649672 | 0.95 | CTSL (0.67) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL30608293 | 0.94 | CTSL (0.69) | CTSLCTSSCTSKMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492523-A2 | METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-01-05 | — | — | EP | disclosed |
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | disclosed |
| WO-2003043631-A2 | METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | RNASE1, GUSB, DPEP1 | CTSL 526/4885CTSS 181/4885CTSK 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.